|
HU222249B1
(hu)
*
|
1991-03-08 |
2003-05-28 |
Amylin Pharmaceuticals Inc. |
Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
|
|
DK0717635T3
(da)
*
|
1993-09-07 |
2000-12-11 |
Amylin Pharmaceuticals Inc |
Fremgangsmåder til reduktion af gastrointestinal motilitet
|
|
US6143718A
(en)
*
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7101853B2
(en)
*
|
1997-05-06 |
2006-09-05 |
Amylin Pharmaceuticals, Inc. |
Method for treating or preventing gastritis using amylin or amylin agonists
|
|
US7910548B2
(en)
*
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
|
AU760609B2
(en)
*
|
1998-01-09 |
2003-05-15 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6087334A
(en)
*
|
1998-08-21 |
2000-07-11 |
Amylin Pharmaceuticals, Inc. |
Anti-diabetic peptides
|
|
ES2316757T3
(es)
*
|
2002-01-08 |
2009-04-16 |
Amylin Pharmaceuticals, Inc. |
Uso de agonistas de amilina para modular trigliceridos.
|
|
AU2003259131A1
(en)
*
|
2002-07-09 |
2004-01-23 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
|
CA2525168A1
(en)
*
|
2003-05-14 |
2004-12-02 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide yy and pyy agonists
|
|
WO2005014022A1
(en)
*
|
2003-07-16 |
2005-02-17 |
Develogen Aktiengesellschaft |
Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
|
JP2008500281A
(ja)
*
|
2004-02-11 |
2008-01-10 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
アミリンファミリーペプチドおよびそれらを作成し使用するための方法
|
|
CA2556923A1
(en)
*
|
2004-02-20 |
2005-09-09 |
Rinat Neuroscience Corp. |
Methods of treating obesity or diabetes using nt-4/5
|
|
US7399744B2
(en)
*
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
US7452868B2
(en)
*
|
2005-03-11 |
2008-11-18 |
Indevus Pharmaceuticals, Inc. |
Controlled release formulations of octreotide
|
|
US7759312B2
(en)
*
|
2005-03-11 |
2010-07-20 |
Endo Pharmaceuticals Solutions Inc. |
Delivery of dry formulations of octreotide
|
|
RU2008131939A
(ru)
*
|
2006-02-02 |
2010-02-10 |
Ринат Ньюросайенс Корп. (Us) |
Способы лечения нежелательной потери веса или нарушений приема пищи агонистами trkb
|
|
JP2009525319A
(ja)
*
|
2006-02-02 |
2009-07-09 |
ライナット ニューロサイエンス コーポレイション |
ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
|
|
US20100086997A1
(en)
*
|
2006-12-20 |
2010-04-08 |
Rinat Enuroscience Corp |
TrkB Agonists for Treating Autoimmune Disorders
|
|
WO2009064298A1
(en)
*
|
2007-11-14 |
2009-05-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity and obesity related diseases and disorders
|
|
JP5622725B2
(ja)
*
|
2008-06-25 |
2014-11-12 |
エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． |
エキセナチド及び他のポリペプチド類の持続的送達
|
|
AU2009262263B2
(en)
*
|
2008-06-25 |
2014-08-14 |
Endo Pharmaceuticals Solutions Inc. |
Octreotide implant having a release agent
|
|
RS59913B1
(sr)
|
2008-10-17 |
2020-03-31 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
|
JP2009149684A
(ja)
*
|
2009-03-11 |
2009-07-09 |
Amylin Pharmaceut Inc |
アミリン作動薬ペプチド用製剤
|
|
BRPI1009392A2
(pt)
*
|
2009-03-12 |
2016-03-08 |
Nordic Bioscience As |
"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
|
|
US20110118178A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
CA2780043C
(en)
|
2009-11-13 |
2019-01-29 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
ES2534191T3
(es)
|
2009-11-13 |
2015-04-20 |
Sanofi-Aventis Deutschland Gmbh |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
|
US20110118180A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
|
SG187904A1
(en)
|
2010-08-30 |
2013-04-30 |
Sanofi Aventis Deutschland |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
RU2650616C2
(ru)
|
2011-08-29 |
2018-04-16 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
|
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
|
BR102013017626A2
(pt)
*
|
2013-06-14 |
2015-02-10 |
Univ Rio De Janeiro |
Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
|
|
ES2887370T3
(es)
*
|
2014-09-04 |
2021-12-22 |
Novo Nordisk As |
Nuevo agonista del receptor de amilina y calcitonina
|
|
SI3229828T1
(sl)
|
2014-12-12 |
2023-06-30 |
Sanofi-Aventis Deutschland Gmbh |
Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|